PIK3CA and neoplasm: Circulating tumor DNA with a TP53 probe was present for the first two collection time points (1 mutation/mL on 8 March 2016 and 2 mutation/mL on 7 June 2016) but then was undetectable for the remaining time points, even when PIK3CA mutations were consistently increasing in patient’s plasma (Figure 3).